Seeking Funding to Explain Granulocyte Cancer Therapy
A press release: "In an effort to accelerate the development of a cancer treatment based on innate cancer immunity, the Direct Oncology (DO) Foundation is launching an appeal to raise $100,000 to sequence cancer resistant mice at Wake Forest University. The project is being coordinated by Livly, a Silicon Valley based non-profit corporation dedicated to the development of sustainable cures for the major diseases plaguing humankind. ... The immune systems of the mice successfully fight off different types of advanced cancer. Immune cells from these Spontaneous Regression / Complete Resistance (SR/CR) mice can be used to protect other mice from advanced cancer. Evidence suggests that there is a single place in the SR/CR mouse's genome that confers the remarkable cancer resistance. Ironically, the gene for the cancer resistance has proven inaccessible to standard mouse genetic methods, and its identity and sequence have remained elusive. The progress of clinical efforts was hampered by lack of knowledge of the genetics underlying the cancer resistance."